🔗 Share this article

As the US proceeds with sweeping adjustments to its vaccine guidelines, an unexpected name has surfaced in a surprising turn: Tracy Beth Høeg, a US-based physician and epidemiologist who initially gained attention by expressing skepticism about COVID-19 shots during the global health crisis and has concentrated on alleged fatalities after COVID-19 immunization in her recent time at the FDA.

Planned Changes to Childhood Vaccine Program

Agency leaders planned to reveal major changes to the pediatric vaccine schedule recently, bringing the US with the Danish national calendar, sources say – a major change that would put the US out of alignment with a large portion of the international standard with little proof for public health gain. The planned update has been delayed until the new year.

Instead of Vinay Prasad, Høeg is set to address the audience at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this year.

A New Direction at the Agency

The acting appointment could signify a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon rolling back long-standing vaccines at the FDA.

The new acting director has often pushed for discontinuing certain pediatric vaccine recommendations in the US to become more similar to the Danish model, a nation with nationalized medicine and a citizenry about the size of Wisconsin’s.

To date comments, she has persisted in emphasizing on vaccines – usually the responsibility of Dr. Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Background

The appointee has no apparent experience in medication creation, regulation or leadership, which has been customary for former leaders of the biologics center. She has been employed at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, stated Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former heads of the center would “grasp regulatory frameworks and the science of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who ran CBER have had.”

CDER has an enormous workload at the agency, she emphasized.

“Everybody just pays attention on the novel medication approvals, but the generic program authorizes a multitude of generic drugs. There is also a biosimilars program, OTC medication office and other areas, and every single one must be supervised,” Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

There is also, a significant leadership aspect to the position, which supervises over 5,000 staff members. “It’s a huge administrative position, if you do it right,” Woodcock said.

Official Statement and Controversial Initiatives

When asked about questions about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among regulatory chiefs on vaccines, a spokesperson said that the “questions stem from incorrect premises”.

“This background aligns with the duties of her position,” the representative explained, pointing to the time Høeg spent guiding the agency head on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg inherits the agency head's controversial fast-track approval initiative, a controversial rapid medication authorization process that allegedly troubled her former heads. “How are these medications being picked for this fast-track system? Who is making the decisions?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the FDA right now.”

Overall, he stated, “the agency appears to be shifting towards less stringent rules of pharmaceuticals, with the exception of shots.”

Established Track Record on Vaccines

Regarding vaccines, Høeg has a more documented, if concerning, past, some experts have noted. She authored a analysis using unverified crowd-sourced reports to assess the incidence of heart inflammation after Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who allegedly have modified findings to imply Covid vaccinations are riskier than they are.

Part of her “policy goals” for the new administration featured changing rules for recently developed shots and ending “unnecessary” vaccines, she said post-election on a podcast. At the FDA, Dr. Høeg has reportedly floated the idea of excluding young men from getting Covid vaccines.

“She is an complete true believer who commences with her preconceived notions and works backwards to accommodate the evidence in a extremely misleading, fraudulent manner,” Howard stated.

Taking Control and a “Push for Payback”

Høeg became part of other skeptics, {like|